Federal judge delays a mifepristone lawsuit until after midterms

# Why This Matters The timing of this delay has direct consequences for millions of Americans seeking abortion access. Mifepristone, which accounts for more than half of all U.S. abortions, remains available during the litigation only because of this postponement—a decision that effectively shields the drug from legal challenge through November's elections. Should the judge rule against mifepristone after the midterms, the ruling could immediately eliminate access to medication abortion across the country, regardless of state laws, since the drug is federally regulated and distributed through a limited network. The delay's proximity to an election cycle that will determine which party controls Congress and potentially appoint future judges raises uncomfortable questions about whether judicial decisions are being timed to avoid political turbulence, undermining the principle that courts operate independently from electoral considerations.